ÂÜÀòÂÒÂ×

Cassandra Choe-Juliak has been in the oncology industry for 16+ years, both in Medical Affairs and in clinical drug development. At Karyopharm, Dr. Choe-Juliak served as the Head of Development for the multiple myeloma and sarcoma programs where she led the development program for selinexor, a first-in-class XPO inhibitor that was approved via accelerated approval. She was most recently the Head of Clinical Development at Affimed GmbH where she was responsible for all of the clinical-stage innate (NK-) cell bispecific engagers including leading AFM13 from Phase 1 to a registration-directed program and developing first-in-human monotherapy and combination trials for AFM24 in EGFR-associated cancers.

Dr. Choe-Juliak received her B.A. from Georgetown University and an M.S. in Pharmacology/Toxicology along with her M.D. from Medical College of Virginia.